NTI initiates First Clinical Site for Phase 3 ASD Trial
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The trial is designed as a multi-centre, randomised, placebo-controlled study targeting core symptoms and neuroinflammatory mechanisms associated with ASD. Monash Children’s Hospital is the first site activated for patient recruitment, with additional sites expected to follow in the coming months.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurotech International Ltd. on 6ix
In the deck
Story so far
Earlier from Neurotech International
- Appendix 4D & Half Year Report
- Positive 90-day GLP toxicology study results in non-rodents
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Quarterly Activities/Appendix 4C Cash Flow Report
- Binding Commitments Received for a $4 Million Placement
Later from Neurotech International
- NTI secures Notices of Allowance for US patent applications
- US FDA clears IND for NTI164
- Neurotech secures $3.15 million R&D tax incentive loan
- NTI164 Phase II/III Autism Data Accepted for Publication
- Trading Halt
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International